Search Results

May 2, 2023

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

Investigational CD20-targeted CAR-Ts Enhance Janssen’s B-cell Malignancy Portfolio Agreement Deepens Janssen’s Leadership in Oncology and Hematology, and Accelerates Commitment to Delivering Transformational Cell Therapies

Innovative Medicine

April 30, 2023

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need

Health & wellness

April 28, 2023

Quiz: How much do you know about stress and mental health?

Stress can do a number on you physically, but there are unexpected emotional and psychological costs, too. Take this quiz to learn more about the surprising effects stress has on your brain.

Caring & giving

April 27, 2023

“My family and I volunteer on a floating hospital that delivers medical care”

Lee-Anne James is a Johnson & Johnson clinical research manager whose home base is Australia. That is, when she and her family aren’t donating their time to Mercy Ships to help treat people who lack access to lifesaving healthcare.

Financial

April 25, 2023

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Financial

April 24, 2023

Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow

Innovative Medicine

April 21, 2023

Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

Approval for AKEEGA® is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated metastatic castration-resistant prostate cancer (mCRPC).1,2 Niraparib in combination with abiraterone acetate (AA), plus prednisone or prednisolone, significantly improved radiographic progression-free survival (rPFS) compared to standard of care in untreated mCRPC patients with BRCA1/2 mutations.3

Innovative Medicine

April 21, 2023

Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Important new data on Janssen’s investigational gene therapy portfolio, including botaretigene sparoparvovec (bota-vec) and JNJ-1887, will be presented

What you need to know about Johnson & Johnson’s 2023 first-quarter earnings

Check out this infographic breakdown of the company’s first-quarter 2023 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Search Results

No Results

Search Results